PRKAB1

PRKAB1 encodes the β1 regulatory subunit of the heterotrimeric AMP-activated protein kinase (AMPK), and through its incorporation into the AMPK complex it governs autophagy, lipid metabolism, and cell-fate decisions across multiple tissues (PMID:28613987, PMID:32611235, PMID:33454005). The β1 subunit serves as a directly druggable node: methyl-β-cyclodextrin binds the AMPK β-subunits to activate the kinase and restore autophagic flux (PMID:28613987), and buddleoside engages PRKAB1 at the ADaM site (residues Val81, Arg83, Ser108), driving AMPK-dependent RPTOR phosphorylation, MTORC1 inhibition, and TFEB-mediated activation of the autophagy-lysosomal pathway (PMID:39936600). PRKAB1-dependent AMPK activity is required for macrophage-mediated hematoma resolution through an ATF1–HO-1/lipid-gene axis (PMID:32611235), for late-stage cardiomyocyte differentiation from iPSCs in an isoform-specific manner distinct from PRKAB2 (PMID:33454005), and for differentiation of colorectal cancer cells, where pharmacological PRKAB1 agonism reactivates CDX2-driven lineage programs and dismantles Wnt/YAP-driven stemness to eliminate cancer stem cells (PMID:41118768). PRKAB1 expression is post-transcriptionally suppressed by miR-802 binding to its 3'-UTR, a regulatory axis controlling hepatic lipogenesis (PMID:33391522, PMID:39309511).

1. 2017 Medium

   Established that the AMPK β-subunits, including PRKAB1, are the direct molecular target through which a small molecule (MβCD) activates AMPK to restore autophagy, defining PRKAB1 as a druggable activation node.

   Evidence siRNA knockdown of PRKAB1/PRKAB2 plus AMPK inhibitor with autophagy flux and cholesterol storage readouts in NPC1-deficient cells

   PMID:28613987

   Open questions at the time

   • No structural or biochemical binding assay localizing the MβCD interaction site
   • Does not distinguish the individual contributions of PRKAB1 versus PRKAB2
2. 2020 Medium

   Demonstrated an isoform-specific developmental requirement, separating PRKAB1 (late cardiomyocyte differentiation) from PRKAB2 (mesoderm specification) in human cardiac lineage commitment.

   Evidence PRKAB1 and PRKAB2 knockout in hiPSCs with RNA-Seq and cardiac marker expression

   PMID:33454005

   Open questions at the time

   • Downstream effectors linking PRKAB1-AMPK to cardiomyocyte maturation undefined
   • Single-lab study without orthogonal rescue
3. 2020 High

   Placed PRKAB1 in an in vivo physiological pathway by showing it is required for macrophage-driven hematoma resolution via an ATF1–HO-1/lipid-gene program.

   Evidence Prkab1-/- mouse perifemoral hematoma model with bone marrow-derived macrophage assays and gene expression analysis

   PMID:32611235

   Open questions at the time

   • Mechanism linking AMPKβ1 to ATF1 activation not resolved
   • Whether the phenotype reflects loss of catalytic AMPK activity or scaffold function untested
4. 2021 Medium

   Defined upstream and downstream pathway context, placing NQO2 as a negative regulator upstream of AMPK/PRKAB1 in flavone-induced autophagy.

   Evidence siRNA knockdown of PRKAB1 and NQO2 in HepG2 cells with LC3-II flux and AMPK phosphorylation western blots

   PMID:34068281

   Open questions at the time

   • Molecular mechanism by which NQO2 restrains AMPK unclear
   • Single cell line
5. 2021 Medium

   Identified post-transcriptional control of PRKAB1, showing miR-802 directly binds its 3'-UTR to suppress expression and modulate hepatic lipogenesis.

   Evidence Dual-luciferase 3'-UTR reporter, miRNA inhibitor/overexpression, RT-PCR and western blot in liver models

   PMID:33391522

   Open questions at the time

   • Human versus mouse target ambiguity (PRKAB1 vs PRKAA1)
   • Physiological conditions that set miR-802 levels not defined
6. 2024 Medium

   Replicated and extended the miR-802/PRKAB1 axis as a therapeutic target by showing schisanhenol protects against NAFLD through this pathway.

   Evidence Liver-specific miR-802 overexpression in NAFLD mice with dual-luciferase 3'-UTR validation and western blotting

   PMID:39309511

   Open questions at the time

   • Direct binding of schisanhenol to PRKAB1 not established
   • Single lab
7. 2025 Medium

   Mapped a direct small-molecule binding site (ADaM site, Val81/Arg83/Ser108) on PRKAB1 and connected it to the AMPK→RPTOR→MTORC1→TFEB autophagy axis in NASH.

   Evidence CETSA, DARTS, molecular docking, and AMPK-inhibition rescue in a mouse NASH model with buddleoside

   PMID:39936600

   Open questions at the time

   • No crystallographic or mutagenesis confirmation of the binding residues
   • Single-lab functional model
8. 2025 Medium

   Established PRKAB1 as a pharmacologically actionable stress polarity sensor whose agonism drives CDX2 differentiation programs and eliminates Wnt/YAP-driven colorectal cancer stem cells.

   Evidence Clinical-grade PRKAB1 agonist tested in CRC cell lines, xenografts, and patient-derived organoids with transcriptomic network analysis

   PMID:41118768

   Open questions at the time

   • Direct target engagement of the agonist on PRKAB1 not biochemically reconstituted
   • Mechanism linking AMPKβ1 to CDX2/Wnt/YAP not molecularly resolved

• How PRKAB1's scaffolding/regulatory role within the AMPK heterotrimer is mechanistically translated into the distinct tissue-specific outcomes (hematoma resolution, cardiac differentiation, CRC differentiation) remains unresolved.
• No structural model of PRKAB1 within AMPK in the timeline
• Whether phenotypes depend on catalytic AMPK output versus β1-specific scaffolding untested
• Direct downstream substrates linking PRKAB1-AMPK to lineage transcription factors unknown